The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Big Pharma has put a Houston pharmacy squarely in the crosshairs of its quest to weed out copycat versions of wildly popular ...

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Pharmaceutical company Eli Lilly announced promising clinical ... could provide an easy-to-administer alternative to other diabetes and obesity drugs. A separate glipron, which has the slightly ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...